Velkommen til

Dansk Selskab for
Klinisk Cannabismedicin

Hvem er vi

Dansk selskab for Klinisk Cannabismedicin


Dansk Selskab for Klinisk Cannabismedicin (DSKCan) blev i 2022 stiftet som del af Lægevidenskabelige Selskaber under Lægeforeningen med det formål at afsøge mulighederne for anvendelse af cannabismedicin i patientbehandlingen og fremme evidensbaseret klinisk forskning inden for området.

Nyeste viden

Se mere
  • 27 maj
    Original: The Journal of Pain

    Analgesic Effect of delta-9-Tetrahydrocannabinol Alone and of a 1:1 delta-9-Tetrahydrocannabinol: Cannabidiol Formulation in Chronic Neuropathic Pain: Two Pilot Studies

    These ongoing preliminary studies explore the efficacy of delta-9-tetrahydro-cannabinol (THC) alone and in a 1:1 combination with cannabidiol (CBD) in subjects with neuropathic pain (NP) in a dose-controlled process using oral formulations. Eligible subjects are 18 to 75 years of age with a diagnosis of NP existing for two or more months, not currently using […]

    Læs mere
  • 27 maj
    Original: Cannabis Cannabinoid Res .

    Anticaries and Antigingivitis Properties of Cannabinoid-Containing Oral Health Products: A Review

    To evaluate the anticaries and antigingivitis properties of cannabinoid-containing oral health products. A systematic research strategy was employed. Specific search terms were used, including “Cannabinoids AND dental caries,” “Cannabinoids AND oral health,” “Cannabinoids AND dental plaque,” “Cannabinoids AND gingivitis AND periodontitis,” “Cannabinoids AND S. mutans,” “Cannabidiol AND oral health,” and “Cannabidiol AND oral biofilm.” The […]

    Læs mere
  • 27 maj
    Original: Cannabis Cannabinoid Res .

    Impact of Dietary Fat and Oral Delivery System on Cannabigerol Pharmacokinetics in Adults

    Background and Aims: Cannabigerol (CBG) is a nonintoxicating cannabinoid synthesized in the Cannabis sativa plant that is incorporated into dietary supplements. This study investigated the influence of dietary fat and an emulsified delivery vehicle on CBG pharmacokinetics (PKs) after oral ingestion by adults. Materials and Methods: Consented participants were enrolled in a double-crossover pilot study and were blinded to the […]

    Læs mere
  • 27 maj
    Original: BMC Neurol .

    An observational time-series study on the behavioral effects of adjunctive artisanal cannabidiol use by adults with treatment resistant epilepsies

    Background: For approximately 30% of people with epilepsy, seizures are not well-controlled by anti-seizure medication (ASM). This condition, called treatment resistant epilepsy (TRE), is associated with increased morbidity and mortality, and substantially impacts the quality of life of both the individual and their family. Non-responsiveness to ASMs leads many people with TRE to seek alternative therapies, […]

    Læs mere